Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMFTAWU)

Drug Name
mRNA-2416 Drug Info
Synonyms mRNA-OX40L
Indication
Disease Entry ICD 11 Status REF
Lymphoma 2A80-2A86 Phase 1 [1]
Ovarian cancer 2C73 Phase 1 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMFTAWU

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
TAX transcriptionally-activated glycoprotein 1 (OX40) TTBW580 TNFL4_HUMAN Replacement [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
TAX transcriptionally-activated glycoprotein 1 (OX40) DTT TNFSF4 5.463 5.875 6 6.276
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Lymphoma
ICD Disease Classification 2A80-2A86
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
TAX transcriptionally-activated glycoprotein 1 (OX40) DTT TNFSF4 9.04E-01 -0.12 -0.21
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT03323398) Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of Moderna Therapeutics.